Sign In
Buy CRSP
$48.15
+1.16 (+2.47%)
At Close: Jul 21, 2026
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
07:26pm, Tuesday, 09'th Aug 2022 Benzinga
Barclays says that CRISPR Therapeutics AG's (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the goal of on-tra
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
02:13pm, Tuesday, 09'th Aug 2022 Benzinga
Upgrades
For Nutrien Ltd (NYSE:NTR), Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. Nutrien earned $5.85 in the second quarter, compared to $2.08 in the year-ago quar
CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss Estimates
01:05pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
CRISPR Therapeutics (CRSP) reports a wider-than-expected Q2 loss. Revenues also miss estimates.
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
11:30am, Tuesday, 09'th Aug 2022 Benzinga
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading.
Needham lowered the price target
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
10:44am, Tuesday, 09'th Aug 2022 Benzinga
Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to
Crispr: My Long-Term 'Wait And Watch' Punt On The Future Of Gene Editing
02:45pm, Monday, 08'th Aug 2022
Crispr Therapeutics is perhaps the most speculative name I'm currently buying, though in small sizes, with an expectation to "don't look, don't sell" for at least 10 years. Analysts expect this compan
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue Estimates
01:15pm, Monday, 08'th Aug 2022 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -7.62% and 96.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
12:00pm, Monday, 08'th Aug 2022 GlobeNewswire Inc.
-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the European Medicines Agency (EMA) and the Medicine
UC Berkeley's Chief Innovation Officer Talks Interest Rates, Crypto, and More
01:45pm, Saturday, 06'th Aug 2022 The Motley Fool
The Federal Reserve could hike short-term interest rates to 4%, and that still might not be enough to cool inflation.
Vertex Q2: Betting Big On Quality Over Quantity
05:07am, Saturday, 06'th Aug 2022 Seeking Alpha
Vertex Pharmaceuticals' investors are enjoying a 24% YTD return and a stellar Q2 earnings report. See what makes VRTX stock a buy now.
Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales Guidance
01:33pm, Friday, 05'th Aug 2022 Zacks Investment Research
Vertex Pharmaceuticals' (VRTX) Q2 earnings and sales beat estimates. The company increases its revenue guidance for 2022.
Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead
04:32am, Friday, 05'th Aug 2022 Benzinga
Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.
For A
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
05:08pm, Wednesday, 03'rd Aug 2022
Gene editing stocks are the talk of Wall Street today as a number of biotech titans enjoy strong gains. It seems a breakthrough clinical trial from Alnylam Pharmaceuticals (NASDAQ: ALNY ) has lifted t
Where CRISPR Therapeutics Stands With Analysts
03:29pm, Tuesday, 02'nd Aug 2022 Benzinga
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
8
8
0
0
L
FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collapses
09:31am, Monday, 01'st Aug 2022
The Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday, leading Beam stock to topple. The post FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collap
